Andi Rroku

Dr. Andi Rroku

Department of Cardiology, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2020 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Open access
PDF file
ARAndi Rroku
Andi Rroku
JKJan Kottwitz
Jan Kottwitz
BHBettina Heidecker
Bettina Heidecker

1 August 2021 in EuroIntervention
Verified
Journal Article
Closed access
EXErion Xhepa
Erion Xhepa
JBJola Bresha
Jola Bresha
MJMichael Joner
Michael Joner
AHAlexander Hapfelmeier
Alexander Hapfelmeier
FRFernando Rivero
Fernando Rivero
AKAdnan Kastrati
Adnan Kastrati
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 February 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
RVRick Volleberg
Rick Volleberg
ARAndi Rroku
Andi Rroku
JMJan-Quinten Mol
Jan-Quinten Mol
RHRenicus S. Hermanides
Renicus S. Hermanides
MLMaarten van Leeuwen
Maarten van Leeuwen
NRNiels van Royen
Niels van Royen
BACKGROUND: Despite fractional flow reserve (FFR)–guided deferral of revascularization, recurrent events in patients with diabetes or after myocardial infarction remain common. This study aimed to assess the association between FFR-negative but high-risk nonculprit lesions and clinical outcomes. METHODS: This is a patient-level pooled analysis of the prospective natural-history COMBINE (OCT-FFR) study (Optical Coherence Tomography Morphologic and Fractional Flow Reserve Assessment in Diabetes Mellitus Patients) and PECTUS-obs study (Identification of Risk Factors for Acute Coronary Events by OCT After STEMI and NSTEMI Patients With Residual Non- Flow Limiting Lesions). Optical coherence tomography was performed on all FFR-negative (FFR >0.80) native nonculprit lesions. Patients or lesions with a high-risk plaque were compared with those without a high-risk plaque. A high-risk plaque was defined in the presence of at least 2 prespecified criteria: (1) lipid arc ≥90 o , (2) minimum fibrous cap thickness <65 µm, and (3) presence of either plaque rupture or thrombus. The primary end points were native major adverse cardiovascular events (composite of all-cause mortality, nonfatal myocardial infarction, or unplanned revascularization excluding stent-failure–related events and nonattributable events) and target lesion failure (composite of cardiac death, target vessel myocardial infarction, or target lesion revascularization). RESULTS: Among 810 patients, 450 (55.6%) had a history of diabetes and 482 (59.5%) presented with myocardial infarction. At least 1 high-risk plaque was identified in 271 (33.5%) patients and 287 (30.6%) lesions. Over a median follow-up of 761 (interquartile range, 731–1175) days, the presence of a high-risk plaque was associated with patient-level native major adverse cardiovascular events (hazard ratio, 2.127 [95% CI, 1.451–3.120]; P <0.001) and lesion-level target lesion failure (hazard ratio, 2.623 [95% CI, 1.559–4.414]; P <0.001). The risk of adverse outcomes increased with the copresence of multiple high-risk features. CONCLUSIONS: FFR-negative but high-risk nonculprit lesions are associated with adverse patient- and lesion-level clinical outcomes. These findings emphasize the additional value of intracoronary imaging in patients with FFR-negative nonculprit lesions. REGISTRATION: URL: https://clinicaltrials.gov ; Unique identifier: NCT02989740; Unique identifier: NCT03857971.

19 February 2019 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
EXErion Xhepa
Erion Xhepa
RBRobert A. Byrne
Robert A. Byrne
FRFernando Rivero
Fernando Rivero
ARAndi Rroku
Andi Rroku
JCJavier Cuesta
Javier Cuesta
AKAdnan Kastrati
Adnan Kastrati

1 October 2019 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
EXErion Xhepa
Erion Xhepa
SCSalvatore Cassese
Salvatore Cassese
ARAndi Rroku
Andi Rroku
MJMichael Joner
Michael Joner
SPSusanne Pinieck
Susanne Pinieck
MFMassimiliano Fusaro
Massimiliano Fusaro

11 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
KJKai Jakobs
Kai Jakobs
LRLeander Reinshagen
Leander Reinshagen
MPMarianna Puccini
Marianna Puccini
JFJulian Friebel
Julian Friebel
AWAnne-Christin Beatrice Wilde
Anne-Christin Beatrice Wilde
URUrsula Rauch
Ursula Rauch
Background: Hemostasis and inflammation are both dysregulated in patients with moderate-to-severe coronavirus disease 2019 (COVID-19). Yet, both processes can also be disturbed in patients with other respiratory diseases, and the interactions between coagulation, inflammation, and disease severity specific to COVID-19 are still vague.Methods: Hospitalized patients with acute respiratory symptoms and with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)-positive (COVpos) and SARS-CoV2-negative (COVneg) status were included. We assessed adenosine diphosphate (ADP)-, thrombin receptor activator peptide 6 (TRAP)-, and arachidonic acid (AA)-induced platelet reactivity by impedance aggregometry, as well as leukocyte subtype spectrum and platelet-leukocyte aggregates by flow cytometry and inflammatory cytokines by cytometric bead array.Results: ADP-, TRAP-, and AA-induced platelet reactivity was significantly higher in COVpos than in COVneg patients. Disease severity, assessed by sequential organ failure assessment (SOFA) score, was higher in COVpos than in COVneg patients and again higher in deceased COVpos patients than in surviving COVpos. The SOFA score correlated significantly with the mean platelet volume and TRAP-induced platelet aggregability. A larger percentage of classical and intermediate monocytes, and of CD4pos T cells (TH) aggregated with platelets in COVpos than in COVneg patients. Interleukin (IL)-1 receptor antagonist (RA) and IL-6 levels were higher in COVpos than in COVneg patients and again higher in deceased COVpos patients than in surviving COVpos. IL-1RA and IL-6 levels correlated with the SOFA score in COVpos but not in COVneg patients. In both respiratory disease groups, absolute levels of B-cell-platelet aggregates and NK-cell-platelet aggregates were correlated with ex vivo platelet aggegation upon stimulation with AA and ADP, respectively, indicating a universal, but not a COVID-19-specific mechanism.Conclusion: In moderate-to-severe COVID-19, but not in other respiratory diseases, disease severity was associated with platelet hyperreactivity and a typical inflammatory signature. In addition to a severe inflammatory response, platelet hyperreactivity associated to a worse clinical outcome in patients with COVID-19, pointing to the importance of antithrombotic therapy for reducing disease severity.